Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

SSRI treatment and activation risk

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Severe reaction after SSRI initiation or increase

New suicidal intent, extreme agitation or akathisia, mania, seizure, collapse, severe confusion with hyponatraemia, or suspected serotonin syndrome with clonus, hyperreflexia, hyperthermia and autonomic instability requires urgent assessment.

Action: Assess ABCDE, temperature, glucose, neuromuscular signs, mental state, all medicines and substances and the timing of dose changes. Protect from self-harm, stop or withhold suspected treatment when clinically indicated, and obtain emergency medical, toxicology and psychiatric advice.

Synopsis

Choose and initiate an SSRI for an evidence-based anxiety, obsessive-compulsive or trauma indication, explain delayed benefit and early activation, monitor suicide and serious adverse effects, and stop treatment gradually.

  • Use an SSRI only for a defined indication after discussing psychological treatment, previous response, bipolar history, suicide and overdose risk, pregnancy, physical modifiers, interactions and patient preference.
  • Match drug and dose to the current SmPC and indication: sertraline starts at 25 mg daily for panic disorder, PTSD and social anxiety but at 50 mg daily for adult OCD.
  • Activation can include increased anxiety, agitation, insomnia and akathisia before benefit; explain it in advance and provide a prompt contact and review plan.
  • For GAD and social anxiety, NICE requires review within one week and weekly suicide monitoring for the first month when an SSRI or SNRI is started in a person under 30.
  • Benefit develops gradually and can take up to twelve weeks in OCD; do not escalate rapidly or label treatment failure before checking dose, duration, adherence and tolerability.
  • Review bleeding risk, hyponatraemia, QT liability for the selected agent, sexual dysfunction and serotonergic interactions, and teach urgent serotonin-toxicity and mania warning signs.
  • SSRIs are not addictive in the same way as benzodiazepines but can cause withdrawal; reduce in stages with smaller decrements at lower doses and adjust to symptoms.

Key red flags

New suicidal planning, intense inner restlessness, impulsivity or rapidly worsening agitation after starting or increasing an SSRI requires same-day risk and medicine review.

Reduced need for sleep with increased energy, pressured speech, grandiosity or disinhibition suggests treatment-emergent mania or an underlying bipolar disorder.

Clonus, hyperreflexia, agitation, sweating, diarrhoea, hyperthermia or autonomic instability after serotonergic exposure suggests serotonin toxicity and requires urgent medical care.

Seizure, severe headache, confusion, marked weakness or reduced consciousness may indicate severe hyponatraemia or another medical complication.

A rapidly emerging unfamiliar syndrome after missed doses or reduction may be withdrawal rather than immediate relapse and should guide reinstatement or taper decisions.

Investigation priorities

01
Pre-prescribing diagnostic reviewFirst step

Confirm indication, severity, bipolar history, suicide risk, substances, pregnancy and previous treatments.

Management branches

InitiationStart one indication-matched SSRI

An adult makes an informed choice for medication and an SSRI is appropriate for the diagnosed disorder.

  1. Check bipolar history, suicide and overdose risk, physical and reproductive modifiers, interactions, previous response and the chosen product's licensed indication.
  2. Explain delayed benefit, activation, common and serious adverse effects, withdrawal and the age- and risk-specific follow-up schedule in writing and conversation.
  3. Prescribe the product-specific starting dose, define any titration interval and target outcome and arrange the first review before the patient leaves.

Key medicines

Sertraline oralFor adult panic disorder, PTSD or social anxiety, give 25 mg by mouth once daily for one week then 50 mg daily; for adult OCD start 50 mg daily; increase by 50 mg no more often than weekly to a maximum of 200 mg daily.Monitor activation, akathisia, suicide risk, mania, bleeding, hyponatraemia, sexual dysfunction and serotonin toxicity; review CYP interactions and avoid MAOIs, and taper gradually to minimise withdrawal.
Escitalopram oralFor adult GAD or social anxiety give 10 mg by mouth once daily, increasing to a maximum of 20 mg daily if needed; for panic disorder give 5 mg daily for one week then 10 mg daily, with a maximum of 20 mg daily.The maximum is 10 mg daily in adults over 65 and in hepatic impairment; assess QT prolongation, hyponatraemia, bleeding, activation, suicide risk, mania, sexual effects and serotonergic interactions.
Open full textbook →Answer 2 questions
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG113 GAD and panic disorder recommendationsSSRI and SNRI activation counselling, age-based monitoring, review and continuation.
  • NICE CG159 social anxiety recommendationsSSRI selection, activation, suicide monitoring and ten- to twelve-week response review.
  • NICE CG31 OCD and BDD recommendationsOCD SSRI delay, titration, akathisia monitoring, continuation and tapering.
  • Sertraline tablets summary of product characteristicsIndication-specific adult starting doses, titration interval, maximum dose and safety.
  • Escitalopram tablets summary of product characteristicsAdult anxiety dosing, age and hepatic limits, QT risk and adverse effects.
  • NICE NG215 dependence and withdrawal recommendationsSlow stepwise antidepressant reduction, smaller low-dose decrements and response to withdrawal.
  • NICE NG222 depression recommendationsCurrent one-week antidepressant review for people aged 18 to 25 or at increased suicide risk.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom